NovoCure Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVCR research report →
Companywww.novocure.com
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
- CEO
- Frank Leonard
- IPO
- 2015
- Employees
- 1,488
- HQ
- Saint Helier, JE
Price Chart
Valuation
- Market Cap
- $2.06B
- P/E
- -11.71
- P/S
- 3.05
- P/B
- 6.13
- EV/EBITDA
- -13.72
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 75.20%
- Op Margin
- -27.19%
- Net Margin
- -25.66%
- ROE
- -50.82%
- ROIC
- -31.75%
Growth & Income
- Revenue
- $655.35M · 8.28%
- Net Income
- $-136,227,000 · 19.21%
- EPS
- $-1.22 · 21.79%
- Op Income
- $-153,800,000
- FCF YoY
- -9.32%
Performance & Tape
- 52W High
- $20.06
- 52W Low
- $9.82
- 50D MA
- $13.26
- 200D MA
- $12.79
- Beta
- 0.90
- Avg Volume
- 1.71M
Get TickerSpark's AI analysis on NVCR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 28, 26 | VERNON W ANTHONY | other | 21,500 |
| Apr 28, 26 | VERNON W ANTHONY | other | 21,500 |
| Mar 4, 26 | Leupin Nicolas | sell | 1,100 |
| Mar 4, 26 | Cordova Ashley | other | 17,638 |
| Mar 3, 26 | Ben Arye Barak | other | 50,125 |
| Mar 3, 26 | Ben Arye Barak | other | 73,340 |
| Mar 3, 26 | Weinberg Uri | other | 50,125 |
| Mar 4, 26 | Weinberg Uri | sell | 6,412 |
| Mar 3, 26 | Weinberg Uri | other | 73,340 |
| Mar 3, 26 | Brackmann Christoph | other | 55,137 |
Our NVCR Coverage
We haven't published any research on NVCR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NVCR Report →